サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1547598

非侵襲的出生前検査の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Noninvasive Prenatal Testing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 233 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.74円
非侵襲的出生前検査の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 233 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

非侵襲的出生前検査市場の世界需要は、調査期間2024-2032年のCAGR0.58%で、2023年の47億1,000万米ドルから2032年にはほぼ49億6,000万米ドルの市場規模に達すると推定されます。

非侵襲的出生前検査（NIPT）は、羊水穿刺や絨毛絨毛サンプリングのような侵襲的な処置に頼ることなく、発育中の胎児の遺伝子異常を特定するために使用されるスクリーニング方法です。NIPTは、母親の血流中を循環する無細胞の胎児DNAを分析し、エドワーズ症候群（18トリソミー）、ダウン症候群（21トリソミー）、パタウ症候群（13トリソミー）などの染色体異常や、特定の性染色体異常のリスクを評価します。NIPTは、従来の出生前検査法と比べてより安全で正確な選択肢を提供し、通常妊娠初期に結果を得ることができます。

市場力学

非侵襲的出生前検査市場を牽引する要因としては、胎児異常の早期かつ正確な検出に対する需要の急増、非侵襲的出生前スクリーニング検査の採用拡大、遺伝子検査技術の進歩などが挙げられます。妊産婦年齢の上昇と出生前スクリーニングの選択肢に対する意識の高まりにより、非侵襲的出生前検査の需要が高まっています。さらに、シーケンス技術、バイオインフォマティクス、遺伝子解析手法の技術進歩がNIPTの技術革新を促進し、胎児遺伝子異常の検出における精度、感度、特異性の向上をもたらしています。さらに、微小欠失や性染色体異数性など、NIPTによってスクリーニングされる遺伝的疾患の範囲が拡大していることは、満たされていない臨床ニーズに対応し、患者ケアを改善することによって、市場の成長をさらに刺激しています。さらに、専門医学会や規制当局によるNIPTの承認、ヘルスケア支払者による払い戻しの適用により、妊婦のNIPTへのアクセスや導入が促進されます。しかし、規制上のハードルと償還の課題は、今後数年間の非侵襲的出生前検査市場の成長を妨げる可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、非侵襲的出生前検査の世界市場における各セグメントを包括的に評価することもできます。非侵襲的出生前検査産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

非侵襲的出生前検査市場レポートのこのセクションでは、国および地域レベルのセグメントに関する詳細なデータを提供し、それによって戦略家が今後の機会でそれぞれの製品やサービスのターゲット層を特定するのに役立ちます。

妊娠期間別

  • 0-12週
  • 13-24週
  • 25-36週

妊娠リスク別

  • 高リスク・平均リスク
  • 低リスク

方法別

  • 超音波検査
  • 生化学スクリーニング検査
  • 母体血漿中無細胞DNA検査

技術別

  • NGS技術
  • アレイ技術
  • PCR法
  • その他

製品別

  • 消耗品・試薬
  • 装置

用途別

  • トリソミー
  • 微小欠失症候群
  • その他の用途

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける非侵襲的出生前検査市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 非侵襲的出生前検査- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 非侵襲的出生前検査の世界市場分析：妊娠期間別

  • 妊娠期間別概要
  • 実績データと予測データ
  • 妊娠期間別分析
  • 0-12週
  • 13-24週
  • 25-36週

第6章 非侵襲的出生前検査の世界市場分析：妊娠リスク別

  • 概要妊娠リスク別
  • 実績データと予測データ
  • 妊娠リスク別分析
  • 高リスク・平均リスク
  • 低リスク

第7章 世界の非侵襲的出生前検査市場分析：方法別

  • 方法別概要
  • 実績データと予測データ
  • 方法別分析
  • 超音波検査
  • 生化学スクリーニング検査
  • 母体血漿中の無細胞DNA検査

第8章 世界の非侵襲的出生前検査市場分析：技術別

  • 技術別概要
  • 実績データと予測データ
  • 技術別分析
  • NGS技術
  • アレイ技術
  • PCR技術
  • その他

第9章 非侵襲的出生前検査の世界市場分析：製品別

  • 製品別概要
  • 実績データと予測データ
  • 製品別分析
  • 消耗品・試薬
  • 器具

第10章 非侵襲的出生前検査の世界市場分析：用途別

  • 概要：用途別
  • 実績データと予測データ
  • 分析：用途別
  • トリソミー
  • 微小欠失症候群
  • その他の用途

第11章 非侵襲的出生前検査の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋セグメント別
    • アジア太平洋国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカセグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカセグメント別
    • 中東・アフリカ国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第12章 非侵襲的出生前検査企業の競合情勢

  • 非侵襲的出生前検査市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品発売
  • その他の開発

第13章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Genesis Genetics（CooperSurgical Inc.）
  • Natera Inc.
  • Centogene N.V.
  • Illumina Inc.（Verinata Health Inc.）
  • Eurofins LifeCodexx GmbH
  • MedGenome Labs Ltd.
  • F. Hoffmann-La Roche Ltd.
  • （Ariosa Diagnostics）
  • Myriad Women'S Health Inc.（Counsyl Inc.）
  • QIAGEN
  • Laboratory Corp. Of America Holdings
  • Progenity Inc.
  • Quest Diagnostics Inc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Gestation Period (USD MN)
  • 0-12 Weeks Market Sales By Geography (USD MN)
  • 13-24 Weeks Market Sales By Geography (USD MN)
  • 25-36 Weeks Market Sales By Geography (USD MN)
  • Analysis By Pregnancy Risk (USD MN)
  • High & Average Risk Market Sales By Geography (USD MN)
  • Low Risk Market Sales By Geography (USD MN)
  • Analysis By Method (USD MN)
  • Ultrasound Detection Market Sales By Geography (USD MN)
  • Biochemical Screening Tests Market Sales By Geography (USD MN)
  • Cell-free DNA in Maternal Plasma Tests Market Sales By Geography (USD MN)
  • Analysis By Technology (USD MN)
  • NGS Market Sales By Geography (USD MN)
  • Array Technology Market Sales By Geography (USD MN)
  • PCR Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Product (USD MN)
  • Consumables & Reagents Market Sales By Geography (USD MN)
  • Instruments Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Trisomy Market Sales By Geography (USD MN)
  • Microdeletion Syndrome Market Sales By Geography (USD MN)
  • Other Applications Market Sales By Geography (USD MN)
  • Global Noninvasive Prenatal Testing Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Noninvasive Prenatal Testing Report
  • Market Research Process
  • Market Research Methodology
  • Global Noninvasive Prenatal Testing Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Gestation Period
  • Market Attractiveness Analysis By Pregnancy Risk
  • Market Attractiveness Analysis By Method
  • Market Attractiveness Analysis By Technology
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Gestation Period (USD MN)
  • 0-12 Weeks Market Sales By Geography (USD MN)
  • 13-24 Weeks Market Sales By Geography (USD MN)
  • 25-36 Weeks Market Sales By Geography (USD MN)
  • Global Market Analysis By Pregnancy Risk (USD MN)
  • High & Average Risk Market Sales By Geography (USD MN)
  • Low Risk Market Sales By Geography (USD MN)
  • Global Market Analysis By Method (USD MN)
  • Ultrasound Detection Market Sales By Geography (USD MN)
  • Biochemical Screening Tests Market Sales By Geography (USD MN)
  • Cell-free DNA in Maternal Plasma Tests Market Sales By Geography (USD MN)
  • Global Market Analysis By Technology (USD MN)
  • NGS Market Sales By Geography (USD MN)
  • Array Technology Market Sales By Geography (USD MN)
  • PCR Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Product (USD MN)
  • Consumables & Reagents Market Sales By Geography (USD MN)
  • Instruments Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Trisomy Market Sales By Geography (USD MN)
  • Microdeletion Syndrome Market Sales By Geography (USD MN)
  • Other Applications Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11214554

The global demand for Noninvasive Prenatal Testing Market is presumed to reach the market size of nearly USD 4.96 Billion by 2032 from USD 4.71 Billion in 2023 with a CAGR of 0.58% under the study period 2024-2032.

Noninvasive prenatal testing (NIPT) is a screening method used to identify genetic anomalies in a developing fetus without resorting to invasive procedures like amniocentesis or chorionic villus sampling. NIPT analyzes cell-free fetal DNA circulating in the mother's bloodstream to assess the risk of chromosomal disorders, including Edwards syndrome (trisomy 18), Down syndrome (trisomy 21), and Patau syndrome (trisomy 13), as well as specific sex chromosome abnormalities. NIPT offers a safer and more accurate option compared to traditional prenatal testing methods, with results typically available early in pregnancy.

MARKET DYNAMICS

The factors driving the noninvasive prenatal testing market include the spurring demand for early & accurate detection of fetal abnormalities, the growing adoption of noninvasive prenatal screening tests, and advancements in genetic testing technologies. With the rising maternal age and the increasing awareness of prenatal screening options, there is a growing demand for noninvasive prenatal testing. Additionally, technological advancements in sequencing technologies, bioinformatics, and genetic analysis methods drive innovation in NIPT, offering improved accuracy, sensitivity, and specificity in detecting fetal genetic abnormalities. Moreover, the expanding range of genetic conditions screened by NIPT, including microdeletions and sex chromosome aneuploidies, further stimulates market growth by addressing unmet clinical needs and improving patient care. Furthermore, the endorsement of NIPT by professional medical societies and regulatory agencies and reimbursement coverage by healthcare payers enhances accessibility and adoption of NIPT among pregnant women. However, regulatory hurdles and reimbursement challenges may hinder the growth of the noninvasive prenatal testing market in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Noninvasive Prenatal Testing. The growth and trends of Noninvasive Prenatal Testing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Noninvasive Prenatal Testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Gestation Period

  • 0-12 Weeks
  • 13-24 Weeks
  • 25-36 Weeks

By Pregnancy Risk

  • High & Average Risk
  • Low Risk

By Method

  • Ultrasound Detection
  • Biochemical Screening Tests
  • Cell-free DNA in Maternal Plasma Tests

By Technology

  • NGS
  • Array Technology
  • PCR
  • Others

By Product

  • Consumables & Reagents
  • Instruments

By Application

  • Trisomy
  • Microdeletion Syndrome
  • Other Applications

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Noninvasive Prenatal Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Noninvasive Prenatal Testing market include Genesis Genetics (CooperSurgical Inc.), Natera Inc., Centogene N.V., Illumina Inc. (Verinata Health Inc.), Eurofins LifeCodexx GmbH, MedGenome Labs Ltd., F. Hoffmann-La Roche Ltd., (Ariosa Diagnostics), Myriad Women'S Health Inc. (Counsyl Inc.), QIAGEN, Laboratory Corp. Of America Holdings, Progenity Inc., Quest Diagnostics Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. NONINVASIVE PRENATAL TESTING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Gestation Period
    • 3.7.2 Market Attractiveness Analysis By Pregnancy Risk
    • 3.7.3 Market Attractiveness Analysis By Method
    • 3.7.4 Market Attractiveness Analysis By Technology
    • 3.7.5 Market Attractiveness Analysis By Product
    • 3.7.6 Market Attractiveness Analysis By Application
    • 3.7.7 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY GESTATION PERIOD

  • 5.1. Overview By Gestation Period
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Gestation Period
  • 5.4. 0-12 Weeks Historic and Forecast Sales By Regions
  • 5.5. 13-24 Weeks Historic and Forecast Sales By Regions
  • 5.6. 25-36 Weeks Historic and Forecast Sales By Regions

6. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY PREGNANCY RISK

  • 6.1. Overview By Pregnancy Risk
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Pregnancy Risk
  • 6.4. High & Average Risk Historic and Forecast Sales By Regions
  • 6.5. Low Risk Historic and Forecast Sales By Regions

7. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY METHOD

  • 7.1. Overview By Method
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Method
  • 7.4. Ultrasound Detection Historic and Forecast Sales By Regions
  • 7.5. Biochemical Screening Tests Historic and Forecast Sales By Regions
  • 7.6. Cell-free DNA in Maternal Plasma Tests Historic and Forecast Sales By Regions

8. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY TECHNOLOGY

  • 8.1. Overview By Technology
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Technology
  • 8.4. NGS Historic and Forecast Sales By Regions
  • 8.5. Array Technology Historic and Forecast Sales By Regions
  • 8.6. PCR Historic and Forecast Sales By Regions
  • 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY PRODUCT

  • 9.1. Overview By Product
  • 9.2. Historical and Forecast Data
  • 9.3. Analysis By Product
  • 9.4. Consumables & Reagents Historic and Forecast Sales By Regions
  • 9.5. Instruments Historic and Forecast Sales By Regions

10. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY APPLICATION

  • 10.1. Overview By Application
  • 10.2. Historical and Forecast Data
  • 10.3. Analysis By Application
  • 10.4. Trisomy Historic and Forecast Sales By Regions
  • 10.5. Microdeletion Syndrome Historic and Forecast Sales By Regions
  • 10.6. Other Applications Historic and Forecast Sales By Regions

11. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Regional Outlook
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.3.2 North America By Segment Sales Analysis
    • 11.3.3 North America By Country Sales Analysis
    • 11.3.4 United States Sales Analysis
    • 11.3.5 Canada Sales Analysis
    • 11.3.6 Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.4.2 Europe By Segment Sales Analysis
    • 11.4.3 Europe By Country Sales Analysis
    • 11.4.4 United Kingdom Sales Analysis
    • 11.4.5 France Sales Analysis
    • 11.4.6 Germany Sales Analysis
    • 11.4.7 Italy Sales Analysis
    • 11.4.8 Russia Sales Analysis
    • 11.4.9 Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.5.2 Asia Pacific By Segment Sales Analysis
    • 11.5.3 Asia Pacific By Country Sales Analysis
    • 11.5.4 China Sales Analysis
    • 11.5.5 India Sales Analysis
    • 11.5.6 Japan Sales Analysis
    • 11.5.7 South Korea Sales Analysis
    • 11.5.8 Australia Sales Analysis
    • 11.5.9 South East Asia Sales Analysis
    • 11.5.10 Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.6.2 Latin America By Segment Sales Analysis
    • 11.6.3 Latin America By Country Sales Analysis
    • 11.6.4 Brazil Sales Analysis
    • 11.6.5 Argentina Sales Analysis
    • 11.6.6 Peru Sales Analysis
    • 11.6.7 Chile Sales Analysis
    • 11.6.8 Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.7.2 Middle East & Africa By Segment Sales Analysis
    • 11.7.3 Middle East & Africa By Country Sales Analysis
    • 11.7.4 Saudi Arabia Sales Analysis
    • 11.7.5 UAE Sales Analysis
    • 11.7.6 Israel Sales Analysis
    • 11.7.7 South Africa Sales Analysis
    • 11.7.8 Rest Of Middle East And Africa Sales Analysis

12. COMPETITIVE LANDSCAPE OF THE NONINVASIVE PRENATAL TESTING COMPANIES

  • 12.1. Noninvasive Prenatal Testing Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13. COMPANY PROFILES OF NONINVASIVE PRENATAL TESTING INDUSTRY

  • 13.1. Top Companies Market Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. Genesis Genetics (CooperSurgical Inc.)
    • 13.3.1 Company Overview
    • 13.3.2 Company Revenue
    • 13.3.3 Products
    • 13.3.4 Recent Developments
  • 13.4. Natera Inc.
    • 13.4.1 Company Overview
    • 13.4.2 Company Revenue
    • 13.4.3 Products
    • 13.4.4 Recent Developments
  • 13.5. Centogene N.V.
    • 13.5.1 Company Overview
    • 13.5.2 Company Revenue
    • 13.5.3 Products
    • 13.5.4 Recent Developments
  • 13.6. Illumina Inc. (Verinata Health Inc.)
    • 13.6.1 Company Overview
    • 13.6.2 Company Revenue
    • 13.6.3 Products
    • 13.6.4 Recent Developments
  • 13.7. Eurofins LifeCodexx GmbH
    • 13.7.1 Company Overview
    • 13.7.2 Company Revenue
    • 13.7.3 Products
    • 13.7.4 Recent Developments
  • 13.8. MedGenome Labs Ltd.
    • 13.8.1 Company Overview
    • 13.8.2 Company Revenue
    • 13.8.3 Products
    • 13.8.4 Recent Developments
  • 13.9. F. Hoffmann-La Roche Ltd.
    • 13.9.1 Company Overview
    • 13.9.2 Company Revenue
    • 13.9.3 Products
    • 13.9.4 Recent Developments
  • 13.10. (Ariosa Diagnostics)
    • 13.10.1 Company Overview
    • 13.10.2 Company Revenue
    • 13.10.3 Products
    • 13.10.4 Recent Developments
  • 13.11. Myriad Women'S Health Inc. (Counsyl Inc.)
    • 13.11.1 Company Overview
    • 13.11.2 Company Revenue
    • 13.11.3 Products
    • 13.11.4 Recent Developments
  • 13.12. QIAGEN
    • 13.12.1 Company Overview
    • 13.12.2 Company Revenue
    • 13.12.3 Products
    • 13.12.4 Recent Developments
  • 13.13. Laboratory Corp. Of America Holdings
    • 13.13.1 Company Overview
    • 13.13.2 Company Revenue
    • 13.13.3 Products
    • 13.13.4 Recent Developments
  • 13.14. Progenity Inc.
    • 13.14.1 Company Overview
    • 13.14.2 Company Revenue
    • 13.14.3 Products
    • 13.14.4 Recent Developments
  • 13.15. Quest Diagnostics Inc
    • 13.15.1 Company Overview
    • 13.15.2 Company Revenue
    • 13.15.3 Products
    • 13.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies